SUMMARY During a 7-month period 33 patients (20 with primary open-angle glaucoma and 13 with suspected glaucoma) were treated with guanethidine 3 % and adrenaline 0 5 % in 1 eyedrop twice daily. The previous therapy was discontinued and the aim of the trial was to treat the patients with GA alone. There was an average decrease in intraocular pressure of 10-8 mmHg or 37-5 % for the whole group (including 5 patients with additional therapy). In eyes with an average IOP in a day-curve without medication equal to or higher than 28 mmHg we found a decrease in IOP of 44-6 % or 14-4 mmHg, and in eyes with an average IOP without medication between 21 and 28 mmHg a decrease of 30-4% or 7-6 mmHg. With GA alone the IOP was 3-3 to 3.9 mmHg lower than on the previous therapy (P <0-05); 46 % of the eyes without additional therapy had all IOPs lower than 22 mmHg and 74% of the eyes had TOPs lower than 22 mmHg except 1 with a peak lower or equal to 25 mmHg 3 hours after application. This peak 3 hours after application indicates that GA has a biphasic action and was significant at the 0 50% level.
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Red eyes and slight ptosis were no problem for most patients. Patients found it very convenient to administer GA only twice daily.
During the last 10 years non-miotic therapy has taken a more important place in the treatment of glaucoma patients suspected of having glaucoma and primary open-angle glaucoma (POAG) . One of the non-miotic preparations used is a combination of guanethidine and adrenaline. Stepanik (1961) , Kutschera (1961) , Kuchle (1961) , Oosterhuis (1962) , and Bonomi and di Comite (1967) reported a fall in intraocular pressure (IOP) with guanethidine 10% alone in the treatment of patients with POAG. This fall was only temporary. Sears (1966) showed in studies on patients with Horner's syndrome 'that the outflow mechanism can be made supersensitive to topical epinephrine'. G. D. and G. Paterson (1972 Paterson ( , 1974 pointed to the phenomenon of hypersensitivity of the receptor for sympathomimetic drugs during chemical denervation with guanethidine and to the necessity of applying adrenaline twice daily during the treatment with guanethidine. Longterm studies on guanethidine and adrenaline in patients with glaucoma have been done by Roth (1973 ), Ftienne (1973 , Crombie (1974 ), Gloster (1974 , Romano (1974 Romano ( , 1977 , Nagasubramanian et al. (1976), and Jones et al. (1977) with good results.
The aim of the trial reported here was to investigate the possibility of stopping all previous therapy of patients known to have POAG or suspected of having glaucoma, to treat them only with guanethidine 3% and adrenaline 0 5% (GA) in 1 eyedrop, and to investigate the proper dosage of GA. New patients with POAG or new glaucoma suspects were, if possible, treated only with GA. Thus we obtained an impression of the efficacy of GA alone and its effect in relation to previous therapy.
Patients and methods
Thirty-three patients (23 male and 10 female) with either POAG or suspected glaucoma were admitted to the trial. They were divided into 20 patients with POAG (33 eyes, 2 eyes having been previously operated on) and 13 glaucoma suspects (26 eyes).
The combination ofguanethidine 3% and adrenaline 05 % in I eyedrop (GA) Table 1 .
After a day-curve without medication all patients started with GA twice daily at an interval of 12 hours (at 9 a.m. and 9 p.m.). The day-curves were repeated after treatment for 1 week, 1 month, 3 months, and 7 months, and then medication with GA was stopped for 2 weeks, when the day-curve was repeated. GA was given after the first pressure reading in the day-curve. Thus the first reading (at zero) gave the IOP 1 2 hours after the last application. Additional therapy was given to patients in whom the IOP was not sufficiently lowered. Every month during the trial the patients were examined at our polyclinic for a short control period when we checked visual acuity, refraction, and IOP, and looked for side effects. Visual fields were controlled during our trial, and we particularly looked for changes in the early defects.
In the group with 20 patients with POAG 2 left the trial (1 patient died suddenly, and 1 left for personal reasons). Additional therapy in this group was needed in 4 patients. One patient needed acetazolamide once daily plus pilocarpine 2% 4 times daily. One (who died suddenly) needed acetazolamide once daily. One needed acetazolamide once daily and carbachol 1 5% 3 times daily. And 1 patient received only pilocarpine 2% twice daily. The rest of the group was controlled with GA twice daily only. In the group with suspected glaucoma 1 patient was taken off medication with GA because of transient serous maculopathy. She was known to have had maculopathy previously. One patient needed additional therapy with pilocarpine 1% twice daily. The rest of the group was controlled with GA twice a day only.
Our results were statistically evaluated by Student's t test. Table 2 show the combined results of all patients treated with GA for about 7 months. The average decrease in IOP for all patients (patients with additional therapy included) was 10-8 mmHg or 37 5%, with a reduction in fall of IOP to 7A4 mmHg or 26-7% after 3 hours. After 7 months' treatment the fall in IOP was still continuing and no adaptation was seen.
Results
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We have selected the eyes of patients who had no additional therapy in 2 groups. The first group with 22 eyes had an average IOP in a day-curve without medication higher than or equal to 28 mmHg. In the second group 25 eyes had an average IOP in a day-curve without medication between or equal to 21 and 28 mmHg (28 mmHg is about the median IOP of the averaged IOPs of the individual day- There was a striking difference in percentage decrease of IOP. It was 44-6% for the eyes belonging to the group with the higher IOPs and 30 4% for the eyes with the lower 1OPs. In Fig. 2 there is a fall in IOP from 31-7 mmHg (average of day-curves without medication) to 17-3 mmHg (average basal level with GA), and in Fig. 3 there is a fall from 24-8 mmHg (average of the day-curves without medication) to 17-2 mmHg (average basal level with GA).
It is interesting to note that, whatever the initial mean IOP was without medication, 24-8 or 31-7 mmHg, there seemed to be a decrease in IOP to a basal limit of 17 mmHg. We do not know the reason for this phenomenon. The results in the individual patients are shown in Table 3 . Twenty-three eyes were well controlled and all had an TOP lower than or equal to 21 mmHg. Twenty-three eyes were controlled and had all TOPs lower than 22 mmHg except at least one peak pressure 3 hours after application in one of the day-curves during treatment. In 14 eyes this peak pressure was lower than or equal to 25 mmHg, and in 9 eyes there were peak pressures between 25 and Among the patients who were treated with GA alone 46% of eyes had all IOPs lower than 22 mmHg during and after the 7-month period, and 74% had all LOPs lower than 22 mmHg with now and then a peak pressure in a day-curve but not higher than 25 mmHg. The patients who needed additional medication were included in the not well controlled group but with a good fall in IOP. The POAG patient with no response at all, had acetazolamide and pilocarpine 2% 4 times daily as additional therapy. The glaucoma suspect with no response had an initial good response on GA but tachyphylaxis developed.
We compared the results of 12 POAG patients and 9 glaucoma suspects, who were treated with GA alone, with the control level they showed on the previous therapy. The results are shown in Table 4 . It indicates that in 18 patients (33 eyes) there was a lower controlling IOP level with GA alone than with previous therapy (3-3 to 3-92 mmHg; P < 0 05). In 1 POAG patient the level with GA alone The combination ofguanethidine 3 % and adrenaline 0'5 % in I eyedrop (GA) in glaucoma treatment was the same and 2 POAG patients (3 eyes) had a higher pressure with GA alone (0-8 mmHg). The number of measurements taken during the previous therapy were 12 5 (range 5 to 25) for the POAG patients and 14 (range 7 to 24) for glaucoma suspects. These were measurements taken during examinations at the polyclinic and not when daycurves were done.
SIDE EFFECTS
Only 2 patients found the drops unpleasant and had cosmetic objections. One of these had severe redness of the eye with chemosis and severe ptosis (more than 3 mm). The other had only moderate hyperaemia of the conjunctiva bulbi et tarsi. Fifteen patients with slight redness and 5 with moderate redness of the eyes had no objections to continuing treatment because of this. Transient or slight ptosis (1 to 2 mm) was found in 7 patients and moderate ptosis (2 to 3 mm) in 2. In 2 patients there was evidence of transient keratoepitheliopathy, but this did not lead to interruption of medication. Six patients had reading problems during the first hours after application. In 4 patients (4 eyes) early visual field defects disappeared and in 1 patient with an absolute visual field defect the defect progressed in spite of an excellent response on IOP. Tachyphylaxis was seen in 1 glaucoma suspect after 3 months' treatment. One patient showed serous maculopathy in 1 eye after 1 month's treatment, which disappeared 3 months later after GA was discontinued. She was known to have maculopathy previously. It was not regarded as a side effect but as progression of the underlying maculopathy.
Discussion
Guanethidine is thought to remove the stored noradrenaline in the granulated vesicles of the sympathetic nerve endings, to block the re-uptake, and to cause a depletion of noradrenaline at the nerve ending. As a result hypersensitivity for sympathomimetics develops at the receptor side. Since the Patersons started to use adrenaline in combination with guanethidine many studies on this subject have been done. Until now GA has not yet gained an important place in the treatment of glaucoma. This is partly owing to the side effects and partly owing to unfamiliarity with GA.
We have carried out this detailed study because we believe that more knowledge about its less well known properties was needed. We consider that we have in GA a potential mixture for lowering IOP, though there is some reduction of the effect on IOP 3 hours after application. This reduction is about 3.5 mmHg for the whole group (P < 0 005). A detailed analysis of this peak effect with GA 3 hours after application will be published elsewhere. The biphasic response during GA treatment has not been previously reported.
In comparison with previous therapy, all patients (except 2 with red eyes) found it pleasanter to administer the drops only twice daily. Hyperaemia of the conjunctivae and slight or moderate ptosis was acceptable to most patients. Visual acuity did not change except in 1 patient known to have progressing cataract. Refraction showed a slight increase in hypermetropia of i to i dioptre in 7 patients. After GA was stopped this disappeared. Relaxation of the ciliary muscle may be the cause of it. Reading problems during the first few hours after application of GA disappeared with I dioptre stronger presbyopia correction for reading. We do not know whether this is due to widening of the pupil or a slight increase in hypermetropia. Reading problems were mainly in patients aged between 40 and 55. Patients who complained of dark vision with miotics lost these symptoms with GA. Widening of the pupil during the first hours after application was frequently seen.
Summarising, we find that with GA, despite red eyes and slight ptosis, we have an effective conservative treatment for patients with suspected glaucoma and POAG. Younger patients, who had many 62fPh. F. J. Hoyng and C. L. Dake problems with miotics, respond particularly well on GA. Operations may be delayed in patients who were not responding to previous therapy. Combinations with other conservative treatments are possible.
